GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » Shiller PE Ratio

Sonoma Pharmaceuticals (STU:O8Z3) Shiller PE Ratio : (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sonoma Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Sonoma Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Shiller PE Ratio Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sonoma Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sonoma Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Shiller PE Ratio falls into.



Sonoma Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sonoma Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Sonoma Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.073/129.4194*129.4194
=-0.073

Current CPI (Dec. 2023) = 129.4194.

Sonoma Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 32.210 99.695 41.814
201406 -0.331 100.560 -0.426
201409 -2.794 100.428 -3.601
201412 -25.182 99.070 -32.896
201503 -4.574 99.621 -5.942
201506 -6.175 100.684 -7.937
201509 -4.330 100.392 -5.582
201512 -7.932 99.792 -10.287
201603 -6.466 100.470 -8.329
201606 -4.886 101.688 -6.218
201609 -3.689 101.861 -4.687
201612 32.763 101.863 41.626
201703 -4.853 102.862 -6.106
201706 -6.568 103.349 -8.225
201709 -5.059 104.136 -6.287
201712 -5.552 104.011 -6.908
201803 -6.788 105.290 -8.344
201806 -4.271 106.317 -5.199
201809 -3.368 106.507 -4.093
201812 -2.083 105.998 -2.543
201903 -1.752 107.251 -2.114
201906 0.478 108.070 0.572
201909 -0.835 108.329 -0.998
201912 -0.648 108.420 -0.774
202003 -0.995 108.902 -1.182
202006 0.115 108.767 0.137
202009 0.051 109.815 0.060
202012 -0.263 109.897 -0.310
202103 -1.529 111.754 -1.771
202106 -0.432 114.631 -0.488
202109 -0.034 115.734 -0.038
202112 -0.274 117.630 -0.301
202203 -0.972 121.301 -1.037
202206 -0.274 125.017 -0.284
202209 -0.333 125.227 -0.344
202212 -0.585 125.222 -0.605
202303 -0.262 127.348 -0.266
202306 -0.268 128.729 -0.269
202309 -0.272 129.860 -0.271
202312 -0.073 129.419 -0.073

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sonoma Pharmaceuticals  (STU:O8Z3) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sonoma Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines